漆原 尚巳

Medicine & Life Sciences

1. Japan 100%
2. Databases 36%
3. Pharmaceutical Preparations 27%
4. Human Influenza 19%
5. Clinical Trials 17%
6. Safety 17%
7. Stevens-Johnson Syndrome 15%
8. Observational Studies 13%
9. Formal Social Control 13%
10. Prescriptions 13%
11. Pediatrics 12%
12. Vaccination 12%
13. Xenopus 12%
14. Health 12%
15. Off-Label Use 12%
16. Raloxifene Hydrochloride 11%
17. Oocytes 11%
18. Health Insurance 11%
19. Cohort Studies 10%
20. Pharmacopoeias 10%
21. Functional Food 9%
22. Postmenopausal Osteoporosis 9%
23. Hydroxymethylglutaryl-CoA Reductase Inhibitors 9%
24. Arsenic 9%
25. Heavy Metals 9%
26. Retrospective Studies 9%
27. Investigational Drugs 9%
28. Hypnotics and Sedatives 9%
29. Herbal Medicine 9%
30. Cholinergic Antagonists 8%
31. Osteoporosis 8%
32. N-Methylaspartate 8%
33. Marketing 8%
34. Confidence Intervals 8%
35. Food 8%
36. Randomized Controlled Trials 8%
37. Pharmacy 8%
38. Ethical Review 8%
39. baloxavir 8%
40. Odds Ratio 7%
41. Life Style 7%
42. Informed Consent 7%
43. Cost-Benefit Analysis 7%
44. Datasets 7%
45. Adaptive Clinical Trials 7%
46. Incidence 7%
47. Drug Utilization 7%
48. Oseltamivir 7%
49. Dopamine Agonists 6%
50. Accidental Falls 6%